Compare Franklin Resources, Inc. (BEN) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Bristol-Myers Squibb Co — how do they compare? Franklin Resources, Inc. trades at $33.57 (market cap $16.95B), while Bristol-Myers Squibb Co trades at $63.94 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.7× Franklin Resources, Inc.'s market cap. Which is the better fit depends on your goals.
| BEN | BMY | |
|---|---|---|
Market Cap | $16.95B | $129.94B |
Sector | Financials | Health |
52-Week High | $35.77 | $65.89 |
52-Week Low | $21.18 | $42.60 |
Enterprise Value | $29.90B | $163.92B |
Dividend Yield | 3.96% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.52, down 0.74% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $0.72, beating estimates, and achieved record AUM of $1.80 trillion as of July 31, 2026, driven by strong inflows and diversification efforts. Valuation ratios include a P/E of 22.69 and P/S of 1.85, while profitability metrics show a net income margin of 8.72%.
The outlook is positive with earnings beats and AUM growth, but risks include weaker ROE of 1.34% and net cash outflows. Analyst consensus price target is $36.50, suggesting potential upside, supported by a 'Buy' rating from 22% of analysts. Investors should monitor margin expansion and competitive pressures in the asset management sector.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
